Sutro Biopharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Sutro Biopharma is gedaald met een gemiddeld jaarlijks percentage van -27.8%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19%. De inkomsten zijn groeide met een gemiddeld percentage van 26.1% per jaar.

Belangrijke informatie

-27.8%

Groei van de winst

-7.2%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	26.1%
Rendement op eigen vermogen	-81.8%
Nettomarge	-73.5%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Oct 11

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Aug 24

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Aug 22

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

Jun 26

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

May 31

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Apr 02

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Mar 28

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Dec 19

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Aug 24

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Feb 10

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Jan 12

Sutro Biopharma: Partnership Progress Warrants Exposure

Aug 16

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Aug 11

Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M

Aug 08

Sutro to get $10M payment from Merck after first patient dosed in collaboration trial

Jul 26

Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts

May 09

Opbrengsten en kosten

Hoe Sutro Biopharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:STRO Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	169	-124	57
31 Mar 24	154	-115	60
31 Dec 23	154	-107	63
30 Sep 23	49	-172	60
30 Jun 23	57	-143	60
31 Mar 23	75	-130	60
31 Dec 22	68	-119	60
30 Sep 22	70	-123	61
30 Jun 22	53	-134	63
31 Mar 22	53	-114	60
31 Dec 21	62	-106	56
30 Sep 21	60	-127	48
30 Jun 21	69	-79	41
31 Mar 21	50	-43	39
31 Dec 20	43	-32	37
30 Sep 20	46	13	38
30 Jun 20	40	-17	36
31 Mar 20	41	-61	34
31 Dec 19	43	-56	33
30 Sep 19	51	-42	32
30 Jun 19	46	-40	29
31 Mar 19	41	-38	25
31 Dec 18	38	-35	22
30 Sep 18	23	-49	18
30 Jun 18	33	-40	18
31 Mar 18	42	-30	17
31 Dec 17	52	-20	16
31 Dec 16	60	0	15

Kwaliteitswinsten: STRO is momenteel verliesgevend.

Groeiende winstmarge: STRO is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: STRO is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 27.8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van STRO over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: STRO is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 13.6% ).

Rendement op eigen vermogen

Hoge ROE: STRO heeft een negatief Return on Equity ( -81.78% ), omdat het momenteel verliesgevend is.

Sutro Biopharma Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS exceeds analyst expectations

Recent updates

Sutro Biopharma, Inc. Announces Initiation of the Registration-Enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-Term Pipeline At Research Forum

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO2024

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Consensus revenue estimates fall by 16%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.1% to US$12.80

Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Price target decreased by 12% to US$12.89

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Consensus revenue estimates fall by 28%

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Medical Officer exercised options and sold US$64k worth of stock

Insider notifies of intention to sell stock

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Price target decreased by 13% to US$14.67

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023

Price target decreased by 9.9% to US$16.89

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold US$53k worth of stock

Chief Business Officer notifies of intention to sell stock

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 10%

Price target decreased by 8.6% to US$17.71

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.1% to US$19.75

Full year 2022 earnings: EPS exceeds analyst expectations

CEO & Director exercised options and sold US$100k worth of stock

CFO & Secretary exercised options to buy US$284k worth of stock.

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Sutro Biopharma, Inc. Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Consensus revenue estimates fall by 18%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

Price target decreased to US$24.63

Sutro Biopharma: Partnership Progress Warrants Exposure

Consensus revenue estimates increase by 51%

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M

High number of new directors

Sutro to get $10M payment from Merck after first patient dosed in collaboration trial

Consensus revenue estimates increase by 24%

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

High number of new directors

Price target decreased to US$26.75

Consensus revenue estimates fall by 14%

Price target decreased to US$28.63

First quarter 2022 earnings: EPS and revenues miss analyst expectations